Microglial Emerging Therapies & Targets under Clinical Trial for Neurodegenerative & Neuropsychiatric Disorders

Time: 12:00 pm
day: Day Two


  • Analyzing the effectivity of anti TREM2 and anti CD33 agonist antibodies currently in clinical trial to improve understanding of the neuroimmunological aspects of Alzheimer’s disease
  • Looking at small molecule P2X7 receptor antagonist, currently in Phase II clinical trial, to enhance knowledge surrounding the neuroimmunological aspects of Major Depressive Disorder
  • Delving into small molecule RIPK1 inhibitor, which is currently progressing towards Phase I clinical trial, to aid comprehension of the neuroimmunological aspects of Amytrophic Lateral Sclerosis and Alzheimer’s disease